Benuvia Operations Signs Licensing Agreement with Medra Brasil for SYNDROS in Brazil

• Benuvia Operations has entered into licensing and supply agreements with Medra Brasil Medicamentos LTDA, enabling Medra Brasil to distribute SYNDROS (dronabinol) in Brazil following regulatory approval.

• The partnership also includes a supply agreement for Benuvia to support Medra Brasil’s development of new CBD products.

Benuvia Operations, a global contract development and manufacturing organisation (CDMO), has announced a new collaboration with Medra Brasil Medicamentos LTDA. The agreement grants Medra Brasil exclusive rights to distribute SYNDROS (dronabinol) in Brazil upon approval from the Brazilian Health Regulatory Agency (Anvisa).

SYNDROS is the first and only FDA-approved tetrahydrocannabinol (THC) liquid cannabinoid treatment for adults, used to manage Chemotherapy-Induced Nausea and Vomiting (CINV) and Anorexia-Associated Weight Loss and Aids (AAWLA). The product has a significant potential in Brazil’s emerging medicinal cannabis market, as the country has seen growing awareness of the therapeutic benefits of cannabis-based medications.

Terry Novak, CEO of Benuvia, expressed excitement about the partnership, calling it an important milestone for the company’s global expansion efforts. He added, “We are thrilled to announce our first out-licensing partnership with Medra Brasil to bring SYNDROS to the people of Brazil.”

In addition to the licensing deal, Benuvia has signed a supply agreement with Medra Brasil, which will enable the development of new CBD products in the Brazilian market. This partnership strengthens Medra Brasil’s position in the country as they work to improve access to innovative cannabis-based treatments.

Amanda Sá, CEO of Medra Brasil, highlighted the importance of the agreement, noting, “More and more people are becoming aware that cannabis medications bring numerous benefits to patients.”